Enantia has once again been granted the Enantia renews Credit d'Impôt Recherche (CIR) accreditation, enabling French pharma & biotech firms to claim R&D tax credits on our services.

The French Ministry of Higher Education and Research has granted Enantia with the Crédit d’Impôt Recherche (CIR) (i.e., R&D tax credit) for a further three-year period: 2023, 2024 and 2025.

 Thanks to the support of Crédit d’Impôt Recherche, French companies can incur research and development costs and be partially reimbursed for these expenses. The objective of this measure is to promote business innovation and competitiveness at national and international level. 

We are glad to share this great news with our French customers, especially those with a strong R&D activity. This includes pharmaceutical companies, biotechs, CDMOs and CMOs, which can benefit from our CIR accreditation in our Analytical, Drug Discovery, API development, and Solid State R&D services.

You can find our CIR accreditation here.